Abbreviations & Acronyms ADHD = attention deficit hyperactivity disorder AVP = plasma arginine vasopressin CR = complete response CS = continued success dDAVP = desmopressin LD = learning disorder MELT = fast-melting oral desmopressin lyophilisate MNE = monosymptomatic nocturnal enuresis M-Uosm = morning urinary osmolality R = relapse Uvol = urine volume Objectives: To investigate renal concentrating ability after long-term fast-melting oral desmopressin lyophilisate treatment in children with monosymptomatic nocturnal enuresis.
Introduction
The International Children's Continence Society recommends alarm therapy or dDAVP as the first-line treatment for primary nocturnal enuresis. 1, 2 Investigations of the therapeutic efficacy of dDAVP have reported complete and partial response rates of 30% and 40%, respectively, and a cure rate of 40-80%. Comparative studies of dDAVP and alarm therapy have shown that dDAVP has an excellent rapid treatment effect, which is maintained with long-term use of ≥6 months, and that dDAVP is superior to alarm therapy. 3, 4 However, dDAVP has a higher relapse rate than alarm therapy. 3 Considering the two main pathophysiological factors of nocturnal enuresis -nocturnal polyuria and a small bladder capacity during sleep, (i) dDAVP treatment is aimed at children with nocturnal polyuria associated with decreased urinary osmolality followed by low overnight vasopressin levels, and (ii) alarm treatment seems to help children with a small bladder capacity for age associated with overactive bladder. Based on these factors for nocturnal enuresis, children with nocturnal polyuria and a small bladder capacity may benefit from a combination of alarm and dDAVP treatment. 5 Intriguingly, the relapse rates are lower with long-term dDAVP therapy than with short-term dDAVP therapy. 6 Furthermore, structured dDAVP withdrawal has lower relapse rates than abrupt dDAVP withdrawal. 7, 8 dDAVP is available as oral tablets, MELT and a nasal spray. G€ okc ße et al. reported that structured withdrawal of MELT treatment decreased the relapse rate after 4 and 12 weeks of follow up. 9 Chiozza et al. investigated the underlying reason for the maintenance of dry nights after long-term dDAVP treatment cessation. These authors found that AVP levels were significantly higher after cessation than before therapy initiation, which was concomitant with the disappearance of wet nights. 10 However, no study has investigated nocturnal renal concentrating ability after long-term MELT treatment, which is currently the standard formulation. The present study investigated the renal concentrating ability of MNE children after long-term MELT treatment by assessing M-Uosm after medication nights and non-medication nights.
Methods
The study patients were outpatient children aged 6-12 years who received MELT from April 2013 to May 2014 for MNE with a frequency of ≥2 wet nights/week over the previous 3 months. Excluded patients were those with previous treatment with dDAVP within the past year, neurogenic bladder, diabetes mellitus, diabetes insipidus, secondary nocturnal enuresis, residual Uvol ≥50 mL or daytime symptoms, including urinary urgency, frequent urination and urinary incontinence. Furthermore, patients who could not follow water restriction after 20.00 hours due to their LD or ADHD were excluded from the present study.
Patients were given 120 lg of MELT 1 h before bedtime after an initial 2-week general lifestyle modification period. Responders were maintained on the same dose, whereas the non-responders were given an increased 240-lg MELT dose, depending on the number of wet nights. Initial non-responders who achieved CR for ≥4 weeks during the treatment at the higher dose had their dose reduced to 120 lg. In patients with CR maintained with ≥4 additional weeks of MELT treatment, the MELT dose was further lowered to 120 lg on alternate days for 8 weeks. The MELT treatment period was defined as the interval from treatment initiation to termination of alternate-day administration.
M-Uosm was measured using urine samples obtained after dry nights before starting alternate-day MELT administration. After voiding sufficiently before going to bed, the families were instructed to collect urine samples from the patients at home on awakening at 08.00 hours the morning after dry nights. Both the patients and their families were instructed to restrict fluid intake of the patients after 20.00 hours on the evening before collection days. On the sample collection days, the children and their families were asked to have breakfast after 08.00 hours. The mean M-Uosm values were calculated from urine samples collected after two medication nights and two non-medication nights in the days before the end of the 8 weeks of alternate-day MELT administration. These urine samples were collected throughout all seasons.
We asked the families to record the nocturnal Uvol by weighing diapers on a digital scale and to measure the morning voided volume using a graduated 10-mL beaker.
Nocturnal Uvol was calculated by adding the difference in diaper weight to nocturia volume and voiding volume. Nocturnal Uvol was calculated from mean Uvol over two medication nights and two non-medication nights in the days before the end of the 8 weeks of alternate-day MELT treatment. Nocturnal Uvol/kg was calculated as Uvol divided by the patient's bodyweight at the initial visit. M-Uosm was determined using an osmotic pressure meter (OSMO STATION; Arkray, Kyoto, Japan) by a cryoscopic method. Nocturnal polyuria was defined as nocturnal urine production >130% of expected bladder capacity for age.
CS was defined as <1 wet night/month, whereas R was defined as ≥1 wet nights/month during alternate-day MELT administration and within 6 months after therapy cessation.
Patients who maintained <1 wet night/month during alternate-day MELT administration or within 6 months after its cessation were assigned to the CS group. Patients who experienced ≥1 relapse during alternate-day MELT administration or within 6 months after its cessation were assigned to the R group. The Mann-Whitney U-test was used to compare the groups; JMP Pro (version 10.0.1; SAS Institute, Cary, NC, USA) was used for statistical analyses; values of P < 0.05 were considered statistically significant.
The present study received approval from the institutional review board of Showa University Fujigaoka Hospital (2015125).
Results
A total of 58 children (43 boys, 15 girls) aged 6-12 years (mean age 9.61 AE 1.80 years) fulfilling the study inclusion criteria were treated for MNE during the study period. Six children with constipation were included among the participants. These children with constipation were treated with laxatives along with general lifestyle modification before administration of MELT. In addition, the participants included two children with ADHD, and one with LD.
The CS and R groups comprised 41 (70.7%) and 17 (30.3%) patients, respectively. Of these, 15 (88.2%) patients experienced relapse during alternate-day administration, and two (11.8%) patients experienced relapse after MELT treatment cessation. The mean duration of treatment was 18.5 months (SD 11.7 months) and 18.3 months (SD 11.3 months) in the CS group and R group, respectively (Table 1) .
There was no significant difference in M-Uosm after medication nights (P = 0.527) between the CS and R groups. However, M-Uosm measured after non-medication nights in the R group was significantly lower than that in the CS group (P < 0.0001). Similarly, nocturnal Uvol was significantly higher in the R group than in the CS group (P = 0.037; Fig. 1) . Furthermore, the difference in M-Uosm values between the medication and non-medication nights was significantly greater in the CS group than in the R group (P < 0.0001). Similarly, the difference in nocturnal Uvol/kg values between non-medication and medication nights was significantly higher in the R group than in the CS group (P = 0.0032).
Discussion
dDAVP, a synthetic analog of vasopressin, is used as an evidence-based treatment for nocturnal enuresis. Through its antidiuretic effect, dDAVP effectively reduces nocturnal Uvol, and it is therefore anticipated to be effective in patients with frequent bedwetting. The cure rate with dDAVP has been reported to be 40-80%; however, up to 83% of pediatric patients experience relapse. 3 Riccabona et al. reported
that an average of 28 weeks of treatment with dDAVP nose drops resulted in complete dryness in 71% of patients, improved dryness in 7% of patients after relapses during or after therapy and improvement in 7% of patients, showing that long-term dDAVP therapy reduces relapse rates. 11 In a follow-up study of 25 individuals suffering from intractable nocturnal enuresis over a 7-year period, L€ ackgren et al. reported that 19 individuals were cured even after dDAVP treatment cessation, and they proposed that, because this rate Non-medication nights Fig. 1 Morning urine osmolality and the nocturnal urine volume per bodyweight (kg) after (a) medication nights and (b) non-medication nights in the continued success and relapse groups. No significant difference was found in morning urine osmolality (P = 0.527) and nocturnal urine volume per bodyweight (P = 0.305) after medication nights between the continued success and relapse groups. Morning urine osmolality after non-medication nights in the relapse group was significantly lower in the continued success group (P < 0.0001). Nocturnal urine volume per bodyweight was significantly higher in the relapse group than in the continued success group (P = 0.046). Lines, 95% confidence interval.
was higher than the expected natural remission rate, longterm dDAVP therapy might remain clinically effective even after its cessation. 12 dDAVP does not affect sleep rhythm, nocturnal waking or bladder capacity; its main effect is reduction of nocturnal Uvol. 13 In contrast, some reports have noted a relationship between the effect of dDAVP and altered sleep rhythm. Muller et al. reported that children with primary nocturnal enuresis treated with dDAVP had a significant improvement of short-term memory. 14 In their experience of treating inherited primary nocturnal enuresis caused by nephrogenic diabetes insipidus with dDAVP, they suggested that dDAVP might have an action not only on the kidney, but also on the central nervous system. 15 In any case, the effect of long-term dDAVP treatment was mainly thought to involve stimulation of an individual's renal concentrating ability, which might lead to full remission through the maintenance of reduced nocturnal enuresis volume even after dDAVP treatment cessation.
In their study of 18 MNE patients, Chiozza et al. administered dDAVP therapy for an average of 305 days and measured plasma AVP levels twice: once before treatment and once 2 years after the conclusion of treatment. 10 These investigators showed that plasma AVP levels 2 years after treatment cessation were significantly higher than those before treatment initiation, suggesting that long-term dDAVP treatment stimulates maturation of the innate production of AVP. In the present study, the plasma AVP level was not measured on the medication and non-medication nights during alternate-day administration; therefore, the difference in plasma AVP level between the two nights is unknown. A possible explanation regarding the increased renal concentration ability that was achieved after cessation of MELT treatment could be that long-term exposure to MELT could cause alterations in the circadian rhythm of renal hormones and renal function. 16, 17 Another possible reason could be that, as recent animal research suggests, dDAVP influences the long-term regulation of aquaporin-2, resulting in modulating the antidiuretic action in the kidney. 18 Various formations of dDAVP are available, such as tablets, nasal spray and MELT. Each has been assessed for reducing nocturnal Uvol, but there is no information on renal concentration ability after MELT treatment. In the present study of MNE patients who were treated with MELT for an average of 18 months, M-Uosm values on non-medication nights were significantly more elevated in the CS group than in the R group. The fact that there were differences in MUosm values between the medication and non-medication nights suggests that the nocturnal renal concentrating ability was more pronounced in the CS group than in the R group, which led to no relapse in the CS group.
The present study measured nocturnal renal concentrating ability using M-Uosm measurements. Folwell et al. reported no difference in the M-Uosm measurements between dDAVP responders and non-responders. 19 However, in these studies, because urine samples were collected not only on dry nights, but also on wet nights, the M-Uosm might not have reflected renal concentrating ability in overnight. In the present study, urine samples were taken only after dry nights and fluid intake restriction after 20.00 hours the previous night; under these conditions, samples were collected on a full bladder after a night during which the participant's last voiding before sample-taking was at 20.00 hours before going to bed. Thus, M-Uosm might be a better parameter to reflect the nocturnal renal concentrating ability of a participant.
In the present study, a CR was maintained during the period of alternate-day administration in the R group, but there were recurrences in two patients after treatment cessation. This suggests that, when M-Uosm is much lower on no medication nights than on medication nights, there is a possibility of recurrence after treatment cessation, which, therefore, requires careful observation.
The present study had several limitations. First, all enrolled patients were outpatients; consequently, the study depended on the families for fluid intake restriction and regulation of urine sample collection times. The families were not asked to measure the volume of the fluid per a day in their voiding charts during the alternate-day MELT administration, even though the family was instructed that the child was to take fluids of 400, 400, and 200 mL in the morning, in the afternoon and from dinner to 20.00 hours, respectively, as part of lifestyle modification before starting MELT treatment. Thus, the possibility cannot be ruled out that better compliance with nocturnal fluid restrictions in the CS group than in the R group might have led to the elevated M-Uosm values observed in the CS group. However, because the comparison between the two groups on medication nights showed comparable M-Uosm levels and nocturnal Uvol, this was not likely a major factor affecting the study outcome. The second limitation was that M-Uosm in the present investigation expressed only the mean osmolality of urine collected overnight, not the maximum concentrating ability. Furthermore, the plasma AVP levels and total urine volumes during the daytime and night-time were also not measured. Because of the absence of such circadian studies, it was not possible to identify the primary pathogenetic factor for the increased renal concentration ability that was achieved after cessation of MELT treatment. Finally, M-Uosm was measured using urine samples obtained only after dry nights before starting alternate-day MELT administration. Therefore, the M-Uosm difference between wet nights and dry nights were not evaluated. In contrast, bedwetting was mainly observed on nonmedication nights in the participants in the R group. The patients in the R group had an average of 4.8 nights of bedwetting per month during alternate-day administration of MELT. Of these, an average of 78% of bedwetting episodes were observed on non-medication nights in the R group. As shown in Figure 1 , the average urine output was significantly lower on non-medication nights than on medication nights. Likewise, there was a more pronounced decrease in the MUosm in the R group on non-medication nights. Based on these findings, increasing urine output without MELT might have been a cause of bedwetting in the present study.
In contrast, an average of 22% of the bedwetting episodes were observed on medication nights. One of the causes of this is that an alteration of functional bladder capacity during sleep could also cause bedwetting on medication nights. Another possibility is that urine osmolality has different values between wet nights and dry nights. Tauris et al. reported that urine osmolality was significantly different between wet and dry nights. 20 Based on this finding, the possibility of a difference in urine output between wet and dry nights on medication nights cannot be excluded. Thus, M-Uosm of dry nights might not be representative of wet nights in this period. This possibility of a difference of M-Uosm between dry and wet nights could be contributing to a large bias. We have to develop a device for collecting urine samples on wet nights under the natural sleep condition, as it is very difficult to collect urine samples on wet nights during sleep in children. It is necessary to investigate the difference in M-Uosm between dry and wet nights; thus, further studies are required to clarify whether a difference in urine osmolality between dry and wet nights exists or not. To eliminate this bias, a prospective study including all the parameters is required.
Despite the various limitations, the results of the present study suggest that patients receiving long-term MELT treatment develop increased nocturnal renal concentrating ability, which results in sustained dryness even after treatment cessation.
